Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 4 of 36« First...23456...102030...Last »

Teva Announces Exclusive U.S. Launch of Generic Version of Reyataz

Teva Pharmaceutical Industries Ltd. announced the exclusive launch of a generic version of Reyataz (atazanavir) capsules in the U.S.

Read More »

Kyprolis improves overall survival in blood cancer

Amgen Inc. said a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

Read More »

PhRMA sues to stop California drug price law

The trade group representing U.S. drugmakers filed a lawsuit to stop California from implementing a law aimed at reining in prescription drug prices.

Read More »

U.S. healthcare spending growth slowed in 2016

Growth in healthcare spending in the United States slowed in 2016 following two years of expansion under the Affordable Care Act.

Read More »

Exclusive: U.S. health regulator Verma eyes new methods for drug pricing

The U.S. government is considering setting new payment methods aimed at curbing costs for Medicare and Medicaid coverage of breakthrough medical treatments with very high prices, particularly novel gene-based therapies for cancer and other diseases, a top health official said.

Read More »

Azar says drug pricing a top priority

Alex Azar – a former drug industry exec who Republicans nominated to run the Department of Health and Human Services – promised to lower drug prices that he said are too high, saying he would look at abuse of patent laws that delays generic competition.

Read More »

Opioid crisis cost U.S. $504 billion in 2015

Opioid drug abuse cost the U.S. economy as much as $504 billion in 2015, White House economists said in a report.

Read More »

PeptiDream Bags R&D Pact With Bayer

Peptidream Inc. scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment of multiple disease targets.

Read More »

CryoPort Grabs Contracts for Gilead, Novartis CAR-T Products

In the world of developing and manufacturing cell-based therapeutics an approved medication for any indication is only part of the business plan. The other aspect is delivering the product to patients. That’s where logistics companies like CryoPort Inc. come into play.

Read More »

U.S. committee recommends GSK shingles vaccine over Merck rival

The committee responsible for U.S. vaccination schedules gave a preferential recommendation to GlaxoSmithKline’s newly approved shingles vaccine Shingrix over Merck’s established product Zostavax.

Read More »

2017 Annual Report: Top 50 Companies – The Corner Turned

For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.

Read More »

Roche bladder cancer drug struggles

Tecentriq has lost market share to Merck & Co.’s rival Keytruda since a study showed Roche’s immunotherapy drug failed to improve overall survival in bladder cancer.

Read More »

House Democrats launch MS drug pricing probe

House Committee on Oversight and Government Reform Democrats are launching an investigation into why prices for MS treatments have nearly quadrupled since 2004.

Read More »

ALS IV therapy Radicava launched in U.S.

Radicava (edaravone), an intravenous therapy indicated for all adult patients diagnosed with Lou Gehrig’s disease, has been launched in the U.S. by Mitsubishi Tanabe.

Read More »

2017 Annual Report – Top 200 Medicines: Humira Remains Atop The Throne

AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.

Read More »

Special Feature – First Year After Launch: The specialties win again

Just like 2016 and the year before, specialty drugs dominate the 2017 list of top performers in the most recent first year after launch class.

Read More »

QuintilesIMS white paper: Large benefit for small numbers

The good news … is that innovation is addressing diseases with high-unmet need such as oncology, autoimmune diseases, and central nervous system (CNS) disorders. But, there is a complicating factor in the economic story: the patient population benefiting from launch brands is becoming smaller.

Read More »

First Year After Launch: New molecular entities launched in the U.S. during 2015 that generated 2016 sales of at least $200 million

A listing of the the new molecular entities launched in the United States during 2015 that generated 2016 sales of at least $200 million

Read More »

Samsung Bioepis launches Remicade biosmiliar

South Korea’s Samsung Bioepis started U.S sales of its copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade.

Read More »

AbbVie Receives CHMP Positive Opinion for Humira

The EMA’s CHMP granted a positive opinion for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients from 2 years of age.

Read More »

Page 4 of 36« First...23456...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom